Why Bristol Myers Squibb Stock Crushed it in February

Core Viewpoint - Bristol Myers Squibb experienced a positive month in February, with a share price increase of over 13%, despite price cuts to its leading drug [1] Financial Performance - The company reported a modest 1% year-over-year growth in fourth-quarter revenue, reaching $12.5 billion, while non-GAAP net income fell nearly 24% to $2.6 billion, or $1.26 per share [2] - The legacy portfolio's revenue declined by 15% to slightly over $5.1 billion, contrasting with a 16% growth in the growth portfolio, led by the cancer drug Opdivo, which generated nearly $7.4 billion [5][4] - Bristol Myers Squibb exceeded consensus analyst estimates, which projected revenue of slightly over $12.2 billion and non-GAAP net income of $1.12 per share [6] Future Guidance - Management provided optimistic guidance for 2026, expecting revenue between $46 billion and $47.5 billion, with adjusted net income of $6.05 to $6.35 per share, surpassing analyst projections [7] - The anticipated revenue range for 2026 is below the 2025 revenue of almost $48.2 billion, primarily due to price cuts for Eliquis [8] Pipeline Progress - The FDA accepted a new drug application for iberdomide for multiple myeloma, and positive results were reported from a Phase 2 trial of Reblozyl for anemia [9] Long-term Outlook - Despite challenges from the legacy portfolio, the strong growth drug lineup suggests a promising future for Bristol Myers Squibb, indicating potential for mid- to long-term success [10]